Study Type: POEM Purpose: Assess the efficacy, safety and tolerability of solifenacin once daily in patients with overactive bladder (OAB). Study Duration: 12 weeks Trial Design: double-blinded, placebo-controlled, modified intention-to-treat, multicenter (84 sites multinational) Drug: solifenacin 5 mg + 1 placebo vs solifenacin 10 mg + 1 placebo vs 2 placebo tablets Patients: 907 patients, mean age ~56, ~82% female, 74 kg, 98% white, ~35% had been treated before, mean number of micturitions per 24 hours is ~12 Inclusion: men and women > 18 years, OAB symptoms for > 3 months, 2 week placebo washout determined the patients, they had to report an average micturition frequency of 8 times or more per 24 hours and at least 3 episodes of urgency during a 3-day diary period Exclusion: published previously Outcomes: Primary end point: micturition times per 24 hours Secondary measures: urgency episodes, incontinence and sleep interruption, micturition volume, pad use
1.
Are the results valid? * randomized? yes * double-blinded? yes * were groups similar? yes * allocation concealment? Not mentioned * all patients accounted for? yes
2.
What were the results:
Solifenacin reduced the number of micturitions by one per 24 hours for either dose.
•
One less incontinence episode every 3 days.
Only the 10 mg dose reduced mean nightly nocturia episodes, equivalent to one less micturition every 5 nights.
• Micturition volume increase from 10.7 ml in placebo group to 36 ml in the solifenacin group • The effect was achieved by 4 weeks. 
Adverse Event

3.
Will the results help me? • Most side effects were mild to moderate in severity.
• The side effects are similar to other antimuscarinic agents.
• The efficacy difference between the 5 mg and 10 mg dose does not warrant the difference in the rate of dry mouth (8% vs 23%).
Conclusion:
In this trial, solifenacin was marginally effective for the treatment of OAB. The mean number of micturitions per day was reduced by one, there was one less incontinence episode every 3 days and one less nocturia episode every 5 nights. Allow 4 weeks of use before assessing efficacy. Side effect rates are similar to the other antimuscarinic agents. The 5 mg dose offers a lower incidence of dry mouth than the 10 mg dose with similar efficacy. For every patient placed on solifenacin, it would cost approximately $100 a month to reduce the number of micturitions by one per day.
